GB
GBIM.US GlobeImmune Inc
- Market cap
- USD 575.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is GBIM.US undervalued?
Graham numberThe Graham number of GlobeImmune Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GlobeImmune Inc fundamental analysis
No fundamental analysis for GlobeImmune Inc yet.
GlobeImmune Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyur…
Full company profileGlobeImmune Inc financial statements
GlobeImmune Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.07M | 5.11M | 14.6M | 22.5M | 5.97M | 6.46M | - | - | - | - |
| Gross Profit | 4.07M | 5.11M | 14.6M | 13.5M | 974K | 3.81M | - | - | - | - |
| Operating Income | -15.8M | -12.6M | -3.97M | 7.69M | -5.82M | -2.77M | - | - | - | - |
| EBITDA | -14.4M | -12.8M | -1.09M | 8.46M | -12.1M | -2.58M | - | - | - | - |
| Net Income | -14.8M | -14.9M | -2.01M | 9.48M | -20.2M | -2.77M | - | - | - | - |
| EPS | -155 | -155 | -21 | 99 | -6.91 | -0.48 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 23.7M | 17.7M | 4.24M | 7.42M | 18.4M | 11.5M | - | - | - | - |
| Total Liabilities | 181M | 200M | 200M | 207M | 12.8M | 8.52M | - | - | - | - |
| Shareholders' Equity | -158M | -182M | -196M | -199M | 5.60M | 2.99M | - | - | - | - |
| Cash & Short-term Investments | 20.3M | 15.2M | 2.00M | 5.92M | 16.8M | 9.90M | - | - | - | - |
| Total Debt | - | - | - | 921K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -17.8M | -5.01M | -13.1M | 3.93M | -10.1M | -7.13M | - | - | - | - |
| Capital Expenditure | 2.38M | 133K | 109K | 12.2K | 294K | 35.7K | - | - | - | - |
| Free Cash Flow | -20.2M | -5.14M | -13.2M | 3.92M | -10.3M | -7.17M | - | - | - | - |
| Ratios | ||||||||||
| ROE | - | - | - | - | -359.6% | -92.6% | - | - | - | - |
| ROA | -62.5% | -83.7% | -47.5% | 127.8% | -109.7% | -24.0% | - | - | - | - |
| Net Profit Margin | -363.6% | -290.9% | -13.8% | 42.1% | -337.8% | -42.8% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GlobeImmune Inc dividends
GlobeImmune Inc has not paid dividends in the last 6 fiscal years.
Who owns GlobeImmune Inc
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 5.75M
- Free float 4.37M
GlobeImmune Inc company profile
- Company name
- GlobeImmune Inc
- Ticker
- GBIM.US
- Exchange
- USA Stocks
- Listed since
- Jul 2, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 1450 Infinite Drive, Louisville, CO, United States, 80027
- Phone
- 303 625 2700
- Website
- globeimmune.com
About GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.
GlobeImmune Inc management
1- Dr. Donald Bellgrau Ph.D.Scientific Founder & Chairman of The Scientific Advisory Board